The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

A mathematical modeling study coordinated by UMC Utrecht has shown that sustained HIV remission (without rebound) or HIV ...

Social barriers were linked to reduced access and low uptake of LAI PrEP and ART for HIV treatment and prevention.

The Trump administration maintains that HIV meds have survived foreign aid cuts. In Zambia, as in other countries, people are struggling to find pills and risk getting sick without medication.

Brosius and his co-conspirators were notified of the false documentation accompanying these drugs but continued purchasing the steeply discounted HIV drugs and reselling them to pharmacy customers ...

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

Real-world data indicated ART with DTG+3TC was effective and well tolerated among patients with HIV infection regardless of prior ART exposure.

Throughout all this, the administration has said that lifesaving medications for people with HIV would, however, continue to flow. But on the ground, we're hearing a very different story.

The Global HIV Drugs Market is valued at USD 34.75 Billion in 2024 and is projected to reach a value of USD 56.5 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 4.55% between 2025 and 2035, ...

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.